TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01805895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
Study: NCT02762032

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PrimaVie Herbal Supplement 125
Description: 125 mg to take BID for 14 weeks in Arm 1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PrimaVie Herbal Supplement 250
Description: 250 mg to take BID for 14 weeks in Arm 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement to take BID for 14 weeks in Arm 3
Study: NCT04036604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes.
Study: NCT01339312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine, serum free
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine, serum free
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Vero Rabies Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Vero Rabies Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03950843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-825
Description: * Dosage Form: capsule~* Dosage: 3 types(low/medium/high dose)~* Frequency: QD(once daily) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration
Study: NCT02117258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-360
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-360
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-360
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
Study: NCT04599231

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of Recovery -15
Description: The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
Study: NCT00597818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: 18 mcg cobiprostone capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: 18 mcg cobiprostone capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: 18 mcg cobiprostone capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
Study: NCT06282991

Intervention type: DRUG
Intervention: Lorlatinib
Description: ALK/ROS1 tyrosine kinase inhibitor
Study: NCT01947348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment with A3 SVF
Description: Treatment interarticular and IV with A3 SVF
Study: NCT04592016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren - Diclofenac sodium gel 1% (GSK, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren - Diclofenac sodium gel 1% (GSK, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel 1% (Perrigo, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion - Pilot
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion - Pivotal
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling - Pilot
Description: 1 sample is taken pre-dose and 24 samples are taken post-dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling - Pivotal
Description: 1 sample is taken pre-dose and 12 samples are taken post-dose.
Study: NCT00676117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole (D961H)
Description: 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Description: 60mg tablet
Study: NCT02974868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg QD during induction and 50 mg QD during Maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg QD during induction and 30 mg QD during maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01755507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUDCA
Description: Comparison of different dosages of norUDCA acid administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUDCA
Description: Comparison of different dosages of norUDCA acid administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUDCA
Description: Comparison of different dosages of norUDCA acid administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02436824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB001 patch
Description: Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
Study: NCT01884597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose ranibizumab
Description: 20mg ranibizumab vials, 0.05ml injected intravitreally, monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose ranibizumab
Description: 20mg ranibizumab vials, 0.05ml injected intravitreally, monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
Study: NCT02116868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry guided analgesia (PP)
Description: Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored remifentanil controlled infusion
Description: The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored antihypertensive drug administration
Description: Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
Study: NCT03710330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 110 ml normal saline IV just before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1gm tranexamic acid
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 gm tranexamic acid
Description: 0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
Study: NCT04566068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention- Adapted Virtual Insomnia Program
Description: 4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control- Enhanced usual care
Description: Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
Study: NCT00485355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic hysterectomy
Description: Total laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic assisted laparoscopic hysterectomy
Description: Robotic assisted laparoscopic hysterectomy with DaVinci robot
Study: NCT02662569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to evolocumab administered by subcutaneous injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to evolocumab administered by subcutaneous injection
Study: NCT02499055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FearFighter
Description: FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
Study: NCT00025389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT00984412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell-transplantation
Description: 2 allogeneic BMTs 6 weeks apart
Study: NCT02895035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine-ketorolac
Description: Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
Study: NCT00967304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of theMen continue and HER DOO2 rule
Description: Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years.
Study: NCT04027088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
Study: NCT03636399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard GIST
Description: 13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive GIST
Description: 13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
Study: NCT00125008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi vaccine
Description: single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
Study: NCT01739140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study: NCT03950843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration
Study: NCT02920580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
Study: NCT00305162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor (P2Y12 inhibitor)
Description: IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (oral P2Y12 inhibitor)
Description: 600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel (oral P2Y12 inhibitor)
Description: 600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bolus & placebo infusion
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules - end of infusion
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules - as soon as possible after randomization
Description: Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
Study: NCT01618968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
Study: NCT00395993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg tablets TID on Days 0 through Day 42